Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Negev Capital is a venture capital firm based in the United States, founded to address the mental health crisis through investments in psychedelic medicine. The fund has a size of $30 million and focuses on early-stage clinical development. They primarily target investments in the USA, Canada, the EU, and Israel.
Negev Capital invests in companies developing psychedelic therapies that are in preclinical or Phase I clinical stages. The firm typically writes checks ranging from $500,000 to $2 million, aiming to support innovative treatments for neurological and psychiatric disorders.
Notable portfolio companies include Mindset Pharma Inc., focused on optimized psychedelic medicines; Beckley Psytech, dedicated to developing psychedelic compounds; and Filament Health, which specializes in natural psychedelic drug development.
Submit your pitch through their form at negevcap.com.
Yes, Negev Capital often leads investment rounds in their portfolio companies, providing both capital and strategic guidance.
Negev Capital is open to follow-on investments, particularly for companies that demonstrate significant progress in their clinical development.
The current fund size of Negev Capital is $30 million, which they allocate towards early-stage psychedelic medicine companies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.